Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Mucopolysaccharidosis VII. Sly Syndrome
Rattus norvegicus
Disease Pathway
Mucopolysaccharidosis type VII (MPS VII), also called Sly syndrome, is a rare inborn error of metabolism (IEM) and autosomal recessive disorder caused by mutations in the GUSB gene. This gene encodes for the beta-glucuronidase enzyme, which normally breaks down glycosaminoglycans (GAGs). However, without beta-glucuronidase, accumulation of GAGs in cells specifically the lysosome increases. The increase in cell size causes tissues and organs to become enlarged as well. This disorder is characterized by macrocephaly, a buildup of fluid in the brain, characteristic facial features, and a large tongue. Other symptoms may include hepatosplenomegaly, heart valve abnormalities, and umbilical or inguinal hernias. MPS VII also causes various skeletal abnormalities, including joint issues and decreased growth. Treatments such as enzyme replacement therapy are still fairly new, however traditionally treatments for Mucopolysaccharidosis VII included symptom relief such as surgery. It is estimated that MPS VII affects 1 in 250,000 individuals.
References
Mucopolysaccharidosis VII. Sly Syndrome References
Sukegawa K, Tomatsu S, Kondo N, Orii T: [Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)]. Ryoikibetsu Shokogun Shirizu. 1998;(19 Pt 2):446-8.
Pubmed: 9645105
Starch and Sucrose Metabolism References
This pathway was propagated using PathWhiz -
Pon, A. et al. Pathways with PathWhiz (2015) Nucleic Acids Res. 43(Web Server issue): W552–W559.
Propagated from PW000532
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings